Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: We investigated the frequency of uveitic macular edema (UME) in patients with different types of noninfectious uveitis and present the primary treatment methods for UME at a specialized eye center in Shaanxi Province, China.
Methods: We conducted a retrospective, noninterventional, observational survey involving 1946 patients with noninfectious uveitis (2816 eyes). The collected data included sex, age of uveitis onset, age of UME onset, anatomical classification of uveitis, and the treatment administered to UME patients.
Results: Of the 1946 patients with noninfectious uveitis, 929 (47.74%) were male and 1017 (52.26%) were female. The average age of all participants in the study was 42.19 ± 15.34 years, with average age at uveitis onset of 39.50 ± 15.52 years. Among the patients, 1003 (51.54%), 239 (12.28%), 410 (21.07%), and 294 (15.11%) had anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis, respectively. UME was observed in 134 (6.89%) of the uveitis patients. The average age of UME patients was 47.33 ± 17.17 years, with average age at uveitis onset of 45.78 ± 17.20 years. Out of the 134 UME patients, 3 (0.30%), 15 (6.28%), 47 (11.46%), and 69 (23.47%) had anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis, respectively. Among them, 37 were lost to follow-up, 44 received adalimumab (ADA) combined with low-dose prednisone and with or without conventional immunosuppressants, 19 received interferon-α2a therapy, 14 received intravitreal corticosteroid injections (such as dexamethasone implant or fluocinolone acetonide), 11 received low-dose corticosteroids combined with conventional immunosuppressants, 5 received only oral prednisone, and 4 received repeated peribulbar or subconjunctival injections of triamcinolone acetonide.
Conclusions: At our tertiary ophthalmic center in Shaanxi Province, China, only 6.89% of patients with noninfectious uveitis were diagnosed with UME. The primary treatment modality for UME in our center is ADA, in accordance with treatment guidelines and the Chinese medical insurance reimbursement system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441883 | PMC |
| http://dx.doi.org/10.1007/s40123-023-00763-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ocular relapse in pediatric acute lymphoblastic leukemia (ALL) is rare and typically associated with central nervous system or bone marrow involvement. Anterior segment infiltration as the sole manifestation of relapse is exceptionally uncommon and may mimic noninfectious uveitis, leading to diagnostic delay. We report the case of a 4-year-old boy with a history of B-cell precursor ALL, diagnosed at age 2 and treated according to the ALL IC BFM 2009 protocol.
View Article and Find Full Text PDFGlucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis.
JAMA Ophthalmol
August 2025
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Importance: Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.
Objective: To evaluate whether being prescribed a GLP-1RA is associated with a reduced risk of developing uveitis.
Machine Learning for Predicting Recurrent Course in Uveitis Using Baseline Clinical Characteristics.
Invest Ophthalmol Vis Sci
August 2025
Programme for Ocular Inflammation & Infection Translational Research, Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.
Purpose: We developed and evaluated machine learning models for predicting the risk of recurrent uveitis using baseline clinical characteristics, to inform clinical decision-making and risk stratification.
Methods: A retrospective analysis was conducted using the Ocular Autoimmune Systemic Inflammatory Infectious Study registry, including 966 patients (1432 eyes) with uveitis. Three machine learning classifiers-random Forest, eXtreme Gradient Boosting, and radial basis function support vector classifier-were trained on preprocessed baseline demographic and clinical data.
Exploring the role of hyperreflective walls as a biomarker for the management of cystoid macular edema.
Int J Ophthalmol
September 2025
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300380, China.
Aim: To investigate the prevalence and clinical implications of hyperreflective walls (HRW) in foveal cystoid spaces in patients with cystoid macular edema (CME) caused by retinal diseases and noninfectious uveitis (NIU).
Methods: This retrospective cross-sectional study included 443 eyes with CME secondary to diabetic macular edema (DME), retinal vein occlusion (RVO), retinitis pigmentosa (RP), neovascular age-related macular degeneration (nAMD), and NIU. Demographic data, HRW features, and other spectral domain optical coherence tomography (SD-OCT) biomarkers were analyzed.
Adalimumab in Focus: Evaluating Effectiveness and Safety in Non-Infectious Uveitis at a Tertiary Referral Center in Türkiye.
Turk J Ophthalmol
August 2025
Eye Protection Foundation, Bayrampaşa Eye Hospital, İstanbul, Türkiye.
Objectives: To evaluate the indications, efficacy, and safety of adalimumab (ADA) in treating active non-infectious uveitis (NIU) in the Turkish population in a real-world setting.
Materials And Methods: This retrospective observational study included patients diagnosed with NIU treated with ADA on-label. The study assessed the impact of ADA treatment on best corrected visual acuity (BCVA), number of immunosuppressive therapies (IST), immunosuppressive drug load, and the frequency of required local treatment.